Nexavar News and Research

RSS
Growing number of countries adopting flexible IP regulations after India issues country's first compulsory license

Growing number of countries adopting flexible IP regulations after India issues country's first compulsory license

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx announces data from regorafenib Phase 3 trial on GIST

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Onyx announces results from regorafenib Phase 3 trial on GIST

Onyx announces results from regorafenib Phase 3 trial on GIST

Indian patent court licenses generic copy of Bayer’s blockbuster anticancer drug

Indian patent court licenses generic copy of Bayer’s blockbuster anticancer drug

First-ever compulsory license issuance in India could have implications for HIV medication

First-ever compulsory license issuance in India could have implications for HIV medication

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Three new targeted drugs can lead to fatal cancer complications

Three new targeted drugs can lead to fatal cancer complications

Enrollment opens in sorafenib vs. radioembolization in advanced hepatocellular carcinoma trial

Enrollment opens in sorafenib vs. radioembolization in advanced hepatocellular carcinoma trial

Survey reveals high interest in Xalkori among medical oncologists

Survey reveals high interest in Xalkori among medical oncologists

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

AVEO third quarter net loss increases to $23.8 million

AVEO third quarter net loss increases to $23.8 million

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011